York and Scarborough Teaching Hospitals NHS Foundation Trust provides a comprehensive range of acute hospital and specialist healthcare services for approximately 800,000 people living in and around York, North Yorkshire, North East Yorkshire and Ryedale - an area covering 3,400 square miles.
Currently we have approximately 100 research studies open to recruitment. The number of patients receiving relevant health services provided or sub-contracted by York Teaching Hospitals in the period 1 April 2020 to 31 March 2021 that were recruited during that period to participate in research approved by a research ethics committee is 4760.
These patients were recruited across a wide range of specialties as most of our hospital now recruits patients into clinical trials. Some areas where we have performed really well are as follows:
- The Trust recruited approximately 1700 participants into phase 4 of the FAST TRACK study during the COVID-19 pandemic. This study compares two stool tests in patients presenting to primary care with bowel symptoms at low risk for colorectal cancer to determine the point of optimal transition from Faecal Calprotectin to FIT for this group of patients.
- York and Scarborough Teaching Hospitals NHS Foundation Trust has been at the forefront of recruitment of patient recruitment into the Recovery Trial, the Trust recruited 221 patients into this trial and remains open to recruitment still. The trial has had two major findings so far; it has demonstrated how dexamethasone was the first drug which could reduce mortality from COVID-19, and also how an anti-inflammatory treatment called tocilizumab reduced the risk of death seen in patients hospitalized with severe COVID-19. The study also highlighted how tocilizumab shortens the required in-patient time and reduces the need for mechanical ventilation so patients can be successfully discharged from hospitals sooner. It is currently the largest global trial of treatments for COVID-19.
- The Trust recruited 29 patients in the REMAP-CAP trial which showed how arthritis drugs helped to reduce mortality and time spent in ICU for those suffering with more severe COVID-19. It has both an innovative and adaptive design to mirror the unpredictable nature of the virus and patients can be randomised into a number of different treatment choices simultaneously. This study randomized patients into multiple arms with the ‘treatment group’ receiving the trial drug and standard care and the ‘control group’ receiving standard care. This is a global initiative with 315 hospital sites taking part and so far the findings have shown tocilizumab, and a second drug called sarilumab, both types of immune modulators called IL-6 receptor antagonists used to treat arthritis have significant impact on patient survival rates, reducing mortality by 8.5%. Equally significant, the findings have also highlighted a number of treatments which have been shown to be ineffective, which is as also helpful and a key part of running a drug trial.
- The R&D department enrolled 361 members of Trust staff into the urgent Public Health England study SIREN which is looking at immunity and reinfection rates within the NHS Staff population. The study has been a huge success and is being used to evidence the effectiveness of the Pfizer vaccine rollout which has supported the UK Government’s COVID strategy and England’s pathway out of Lockdown.
- The Trust has been actively participating in the Urgent Public Health Study; Clinical Characterisation Protocol for Severe Emerging Infections (CCP) since the beginning of the COVID-19 pandemic, and has recruited 1789 patients so far. It aims to inform clinical practice and management of the pandemic through globally collecting patient data on various markers such as the clinical features of COVID-19, patient symptoms and responses to treatments. It has provided one of the largest databanks of information on the virus so far.
- The SSHeW trial has shown clear evidence how the 5* GRIP-rated, slip-resistant shoes provided by the study reduced the number of slips NHS staff had at work. Staff who were provided with these shoes had fewer slips than those staff members who wore their own shoes at work
- So far, the Trust has recruited 119 patients into the Urgent Public Health Study, Genetics Of Mortality In Critical Care (GenOMICC). The study collects DNA samples of patients severely unwell in ICU with conditions, such as COVID-19, in the hope genes can be analysed and identified which may provide insight as to why some people become more severely unwell than others and why people react differently to different infections.
We are proud to be a partner with the Hull York Medical School (HYMS) in providing clinical placements and training for future doctors at Scarborough and York Hospitals. As a Teaching hospital our researchers and academics have a strong track record of clinical and research excellence across the majority of our clinical directorates.
The Research and Development Office will guide you through the research process, whether you are simply wanting to complete a research questionnaire or need advice on the complex process of study set-up and initiation. We aim to offer very high quality services to researchers and clinicians across all our clinical directorates by offering advice and guidance in such areas as:
- Finding and applying for research grants
- Study design
- Health Research Authority (HRA) Approval
- Research Ethics applications
- Day to day management of studies
- Quality assurance and data management
- Patient & Public Involvement
- Publication and dissemination
- Intellectual Property
- Grant costings and finances
We are currently research active in the following clinical areas but we are always on the lookout to develop research in new areas:
- Obs & Gynae
- Sexual Health
Research & Development Office flyer